Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.

Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.

Videos

Dr. Geynisman on Patient Preferences for Treatment of RCC

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma (mRCC).

Patients are excited and willing to participate in clinical trials of immunotherapy, says Geynisman. In RCC, select patients have shown to derive benefit from immunotherapy.

Geynisman says that trials of immunotherapy and targeted therapies will undoubtedly change the treatment paradigm in mRCC.

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.

Dr. Geynisman Discusses Immunotherapy in RCC

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Currently, tyrosine kinase inhibitors (TKIs) are given first, followed by drugs such as nivolumab (Opdivo), cabozantinib (Cabometyx), and lenvatinib (Lenvima) plus everolimus (Afinitor), states Geynisman.

Every patient is unique and has different needs and comorbidities. There are a number of options so determining treatment depends on the patient.

Daniel M. Geynisman, MD

Articles

Dr. Geynisman on Patient Preferences for Treatment of RCC

Dr. Geynisman Discusses Immunotherapy in RCC

Dr. Geynisman on Sequencing of Agents for Kidney Cancer